You seem to be asking a rhetorical question but I can't help myself.....
I wonder why the trial has been put in with coronary revascularisation trials?
From http://www.mesoblast.com/science/mechanisms-of-action
MPC-150-IM is designed for local delivery to damaged heart muscle and to allow the MLCs to secrete biomolecules involved in myocardial neovascularization, cardiomyocyte survival, cardiomyocyte precursor migration and proliferation, and reduction in fibrosis and myocardial scarring. Biomolecules include stromal cell-derived factor 1, Angiopoietin-1, vascular endothelial growth factor (VEGF), hepatocyte growth factor, and matrix metalloproteinases.
Bold my emphasis
If you want to revascularise why not get the heart to do it with a little help.
- And then last is the results of the MSB trial.
I guess they were keeping the best till last
- Forums
- ASX - By Stock
- MSB
- Ann: End-Stage HF Results Selected For AHA Scientific Sessions
Ann: End-Stage HF Results Selected For AHA Scientific Sessions, page-49
-
- There are more pages in this discussion • 39 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
99.0¢ |
Change
0.010(1.02%) |
Mkt cap ! $1.130B |
Open | High | Low | Value | Volume |
99.5¢ | $1.02 | 98.5¢ | $5.507M | 5.501M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 9996 | 99.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
99.5¢ | 18069 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 9996 | 0.990 |
2 | 32880 | 0.985 |
4 | 71034 | 0.980 |
2 | 3059 | 0.975 |
7 | 145890 | 0.970 |
Price($) | Vol. | No. |
---|---|---|
0.995 | 1132 | 1 |
1.000 | 9500 | 3 |
1.005 | 35000 | 1 |
1.010 | 58113 | 4 |
1.015 | 46100 | 3 |
Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
SPONSORED BY The Market Online